Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes due to the lack of hormone receptors and human epidermal growth factor receptor 2 (HER2) amplification, which limits therapeutic options and contributes to poor prognosis [1]. The gene discussed is ERBB2; the disease is breast carcinoma.